Red Yeast Rice: Benefits, Forms, Dosing, and Side Effects

Red yeast rice (RYR) is a substance produced by fermenting white rice with the mold Monascus purpureus. It has been used in East Asian cuisine and traditional Chinese medicine for over 1,000 years, dating back to at least 800 AD during the Tang Dynasty [1][2][3]. The primary bioactive compound is monacolin K, which is chemically identical to the prescription drug lovastatin — one of the first statin drugs approved for lowering cholesterol. Red yeast rice also contains other monacolins, Monascus pigments, GABA, and antioxidant compounds that may contribute synergistically to its effects [1][2][6].

Despite regulatory complexity — the FDA considers products with more than trace amounts of lovastatin to be unapproved drugs — red yeast rice remains one of the most extensively studied natural products for cholesterol management. The landmark China Coronary Secondary Prevention Study (CCSPS) demonstrated meaningful reductions in LDL cholesterol, cardiovascular events, and mortality in nearly 5,000 patients followed for 4.5 years [1][2][9]. This article provides a comprehensive, evidence-based review of the benefits, forms, dosing, safety, and drug interactions of red yeast rice.

Table of Contents

• Overview
• Forms and Bioavailability
• Evidence for Benefits
• Recommended Dosing
• Safety and Side Effects
• Drug Interactions
• Dietary Sources
• References

Overview

Red yeast rice (RYR) is a substance produced by fermenting white rice with the mold Monascus purpureus. It has been used in East Asian cuisine and traditional Chinese medicine for over 1,000 years, dating back to at least 800 AD during the Tang Dynasty [1][2][3]. In traditional Chinese cooking, red yeast rice serves as a natural red pigment, flavor enhancer, and food preservative — it colors and flavors meats such as char siu (barbecued pork) and Peking duck, and features in fermented products like red bean curd (tofuyo), rice vinegar, and rice wines [2][3].

The primary bioactive compounds in red yeast rice are a family of molecules called monacolins (also known as mevinic acids). The most important of these is monacolin K, which is chemically identical to the prescription drug lovastatin (brand name Mevacor) [1][4][5]. Lovastatin was one of the first "statin" drugs approved for lowering cholesterol, and it works by inhibiting the enzyme HMG-CoA reductase — the rate-limiting enzyme in the body's cholesterol biosynthesis pathway [1][4]. By blocking this enzyme, monacolin K upregulates LDL receptor expression in the liver and reduces circulating LDL cholesterol [2].

Red yeast rice also contains monacolin KA, the hydroxy acid (activated) form of lovastatin, which is the form that is active after lovastatin passes through the liver [1]. Together, monacolin K and monacolin KA (collectively referred to as "total lovastatin") are typically the predominant monacolins in red yeast rice [1]. Beyond monacolins, red yeast rice contains other secondary metabolites including Monascus pigments (natural red-orange colorants), gamma-aminobutyric acid (GABA), dimerumic acid (an antioxidant), sterols, isoflavones, and various phenolic compounds that may contribute to its overall pharmacological profile [2][3][6].

A critical distinction between red yeast rice and prescription lovastatin is dose. The total amount of lovastatin in clinically tested red yeast rice preparations typically ranges from about 5 mg to 18 mg per day — less than half the standard prescription dose of lovastatin (20-40 mg) used to achieve 30-40% LDL reductions [1]. A likely explanation for why red yeast rice achieves meaningful cholesterol-lowering effects at these lower lovastatin doses is that it contains a variety of other monacolins and bioactive compounds that may contribute synergistically to cholesterol lowering [1][2].

The regulatory status of red yeast rice is complex, particularly in the United States. The FDA has determined that red yeast rice products containing more than trace amounts of lovastatin are technically unapproved drugs, because lovastatin was approved as a pharmaceutical ingredient before it was marketed as a dietary supplement [1][4][5]. Supplement labels in the US typically list only the amount of red yeast rice per serving — not the amount of monacolins — making it very difficult for consumers to compare products [1]. In Europe, the European Food Safety Authority (EFSA) has mandated that red yeast rice products contain less than 3 mg of monacolins per daily serving as of June 2023, and labels must show the monacolin content [1][7].

These regulatory constraints mean that the red yeast rice products available on the market vary enormously in their monacolin K content — from undetectable amounts to pharmacologically significant levels — creating significant challenges for both consumers and clinicians [4][5][8]. Despite these challenges, red yeast rice remains one of the most extensively studied natural products for cholesterol management, with several well-designed clinical trials and large-scale outcome studies demonstrating meaningful reductions in LDL cholesterol, cardiovascular events, and mortality [1][2][9].

Forms and Bioavailability

Standard Red Yeast Rice

The most common form of red yeast rice on the supplement market is ground or encapsulated fermented rice powder. Products typically contain 600 mg of red yeast rice per capsule, with the daily serving ranging from 1,200 mg to 4,800 mg depending on the product and clinical indication [1]. The monacolin K content varies enormously across products. A 2017 analysis of 28 brands from mainstream US retailers found that none listed monacolin K quantity on the label; monacolin K was not detected in two brands, and in the remaining 26, the quantity ranged more than 60-fold, from 0.09 to 5.48 mg per 1,200 mg of red yeast rice [5][8]. A 2010 examination of 12 proprietary products similarly found up to 100-fold variation in monacolin levels [8][10].

This variability arises from differences in Monascus purpureus strains, fermentation conditions, and manufacturing processes [2][8]. Furthermore, monacolin K levels may change over time within a given product, as the compounds can degrade during storage [1].

Xuezhikang (Standardized Extract)

Xuezhikang is a partially purified extract of red yeast rice developed in China, standardized to contain approximately 2.5-3 mg of monacolin K per 600 mg dose [2][9]. It is the formulation used in the landmark China Coronary Secondary Prevention Study (CCSPS) and several other major clinical trials [9][11]. Xuezhikang represents the best-studied red yeast rice preparation for cardiovascular outcomes. It is taken as 600 mg two to three times daily (1,200-1,800 mg/day total), providing approximately 10-12.8 mg of total lovastatin daily [1][9].

Ankascin 568-R Plus

A very different type of red yeast rice product is Ankascin 568-R Plus (Sunway Biotech Co., Ltd., Taiwan), which contains an extract focusing on two compounds — ankaflavin and monascin — rather than the lovastatin-type monacolins normally found in red yeast rice [1]. It was accepted by the US FDA as a new dietary ingredient in 2018. An 8-week, placebo-controlled study in 40 people with metabolic syndrome found a 19% decrease in LDL cholesterol versus 1.9% with placebo, with no negative effects on liver, kidney, or thyroid function. However, there was no significant decrease in fasting blood glucose or triglycerides, one study author was employed by the manufacturer, and additional independent research is needed [1][12].

Red Yeast Rice + CoQ10 Combinations

Because monacolins in red yeast rice (like prescription statins) can deplete the body's endogenous coenzyme Q10 (CoQ10) levels by blocking the mevalonate pathway, many commercial products include supplemental CoQ10 (typically 100 mg per serving) [1][2][13]. A 2016 trial of red yeast rice plus CoQ10 in moderately hypercholesterolemic subjects demonstrated significant improvements in LDL cholesterol (-26.3%), endothelial reactivity (+6.0%), and arterial stiffness (pulse wave velocity -4.7%) compared to placebo [13]. CoQ10 can itself modestly lower cholesterol levels when taken alone [1].

Red Yeast Rice + Nattokinase Combinations

Red yeast rice is frequently combined with nattokinase in supplements targeting cardiovascular health. A 2009 study showed the combination significantly improved lipid profiles more potently than nattokinase alone [14]. A 2024 study in coronary artery disease patients demonstrated superior reductions in triglycerides, total cholesterol, diastolic blood pressure, and prothrombotic markers with the combination outperforming individual components [14]. However, a separate 2024 study among 178 adults with stable coronary artery disease found that adding nattokinase to red yeast rice (providing 9 mg monacolins) did NOT produce significantly greater cholesterol reductions over three months [15].

Key Bioavailability Considerations

Monacolin K exists in two forms: the lactone form (inactive prodrug, identical to lovastatin in tablets) and the hydroxy acid form (monacolin KA, the biologically active form) [1]. Both are present in red yeast rice in varying ratios. Lovastatin is metabolized primarily through the CYP3A4 enzyme pathway in the liver and intestine [1][2][16], which has important implications for drug interactions and timing. Since most cholesterol synthesis occurs at night, taking red yeast rice at bedtime maximizes its effect — the same rationale behind bedtime dosing of many prescription statins [1][17]. One study noted improved bioavailability of lovastatin in red yeast rice compared to synthetic lovastatin, possibly due to the food matrix of the fermented rice [18].

Evidence for Benefits

Cholesterol and Lipid Lowering

Red yeast rice's cholesterol-lowering effects are supported by a substantial body of clinical evidence from multiple randomized controlled trials and meta-analyses.

Foundational trial — Heber 1999. The first rigorous RCT enrolled 83 adults with elevated LDL cholesterol (135-250 mg/dL). A red yeast rice supplement (Cholestin) providing approximately 7 mg of total lovastatin per day (four 600 mg capsules) for 12 weeks produced average reductions of 21% in total cholesterol (from 256 to 203 mg/dL), 31% in LDL cholesterol (from 174 to 120 mg/dL), and 34% in triglycerides (from 197 to 130 mg/dL). HDL did not change significantly. Adverse events were comparable to placebo [1][19].

Combined with lifestyle changes — Becker 2008. When red yeast rice (18 mg total lovastatin, or 27 mg if LDL exceeded 160 mg/dL) was combined with AHA-recommended lifestyle changes and fish oil, a 42% decrease in LDL cholesterol was achieved — demonstrating additive effects [1][20].

Combined with Mediterranean diet — Mazza 2018. Red yeast rice (10 mg lovastatin) plus 30 mg CoQ10, given with a Mediterranean diet, lowered cholesterol beyond what diet alone achieved and also reduced blood pressure and blood glucose [1][21].

Early 2000s trials. A 2002 randomized study of 74 hypercholesterolemic patients using red yeast rice (600 mg twice daily) reported 19-27% LDL reductions over 8 weeks, with sustained tolerability [2][22].

Low-dose efficacy — Minamizuka 2021. Even 200 mg of red yeast rice once daily (just 2 mg lovastatin) in 19 people with borderline to high LDL cholesterol reduced LDL by 37.12 mg/dL vs. 7.7 mg/dL in diet-alone group over eight weeks. However, the study was industry-funded, lacked placebo control, and excluded responders to diet alone [1][23].

2022 meta-analysis (15 RCTs, n=1,012). Significant reductions in total cholesterol (MD -17.80 to -31.10 mg/dL), LDL cholesterol (MD -14.40 to -27.91 mg/dL), and triglycerides (MD -19.90 to -26.32 mg/dL), with modest HDL increases. LDL reductions averaged 15-34% with 5-10 mg monacolin K [2][24].

2024 meta-analysis (14 RCTs, n=705). Mean reductions of 37.43 mg/dL in total cholesterol (95% CI: -47.08 to -27.79) and 35.82 mg/dL in LDL cholesterol (95% CI: -43.36 to -28.29; I-squared=34%). Effects approximate low-dose statin therapy [2][25].

Adjunct to non-statin medications. A case report of a 47-year-old woman with statin intolerance and familial hypercholesterolemia showed that adding red yeast rice (3 mg lovastatin) and berberine (500 mg) to evolocumab and ezetimibe further lowered LDL from 115 to 68 mg/dL [1][26].

Plant sterol add-on. Adding 900 mg plant sterols to red yeast rice (7 mg lovastatin) did NOT further reduce LDL beyond red yeast rice alone after one year — both groups achieved ~25% reductions. This surprised researchers, as sterols added to prescription statins typically produce an additional 7-10% LDL reduction. Participants in a lifestyle modification program had 1.6 times greater chance of reaching target LDL [1][27].

Cardiovascular Outcomes and Mortality

The most important evidence for red yeast rice comes from studies examining hard cardiovascular endpoints.

China Coronary Secondary Prevention Study (CCSPS). This landmark trial enrolled 4,870 Chinese patients with prior myocardial infarction (mean age 61) and followed them for 4.5 years [2][9][11]. Participants received Xuezhikang (600 mg three times daily, ~10-12.8 mg total lovastatin) or placebo:

• LDL cholesterol reduced by 20%; HDL increased by 4%
• 45% relative risk reduction (4.7% absolute) in major coronary events
• 30% reduction in cardiovascular mortality
• 33% reduction in total mortality
• One-third reduction in coronary revascularization procedures

2020 meta-analysis (7 RCTs, n=10,699). Red yeast rice (typically 1,200 mg/day) significantly lowered the risk of nonfatal MI (RR 0.42, 95% CI 0.34-0.52), revascularization (RR 0.58, 95% CI 0.48-0.71), and sudden death (RR 0.71, 95% CI 0.53-0.94). Fatal MI was not significantly reduced (RR 0.78, 95% CI 0.55-1.10) [2][28].

2024 meta-analysis. Linked red yeast rice to a 15-20% reduction in major adverse cardiovascular events in MI patients with borderline hypercholesterolemia. Evidence quality was rated moderate [2][29].

Limitation: Direct evidence for cardiovascular endpoints outside Chinese cohorts is sparse. Most Western studies focus on lipid profiles rather than clinical events [2].

Tolerability in Statin-Intolerant Patients

Becker 2009. Among patients with confirmed statin intolerance, only 7% reported muscle pain when switched to red yeast rice (4.9 mg total lovastatin, three 600 mg capsules daily) [1][30].

Xue 2017. A 4-week comparison of red yeast rice (300 mg four times daily, 10 mg lovastatin) vs. simvastatin (20 mg) showed similar cholesterol-lowering but slightly more muscle fatigue and reduced physical activity with simvastatin [1][31].

Venero 2010. Among statin-intolerant patients using self-selected red yeast rice (1,200 mg at bedtime), 92% tolerated it and achieved an average 21% LDL reduction [1][32].

2023-2024 data. A study of 55 statin-intolerant familial hypercholesterolemia patients reported up to 25% LDL reductions with 10 mg monacolin K daily over 8 weeks, without exacerbating myopathy [2][33]. A systematic review found no significant differences in lipid-lowering outcomes between red yeast rice and simvastatin [2][34].

Liver Cirrhosis Risk

An analysis of 68,734 Taiwanese patients found red yeast rice associated with a 40% lower risk of liver cirrhosis vs. prescription lovastatin over 3-6 years, with about half the risk of postcirrhosis complications. However, this was observational, not a clinical trial [1][35]. A separate 2024 cohort of over 100,000 patients found a similar 40% lower cirrhosis incidence (adjusted HR 0.60) among red yeast rice users [2][36].

Diabetes and Glucose Metabolism

Statin drugs are associated with a 2.2-fold increased risk of new-onset type 2 diabetes [1][37]. Red yeast rice appears to carry substantially lower risk and may be protective.

A large Taiwanese study found red yeast rice users had a 54% lower diabetes risk vs. lovastatin users over 5 years, with higher red yeast rice doses associated with lower risk [1][38]. A 2022 meta-analysis found red yeast rice reduced fasting glucose by 0.28 mmol/L, HbA1c by 0.32%, and HOMA-IR by 0.65 units, particularly in metabolic syndrome patients [2][39].

Anti-Inflammatory and Antioxidant Effects

In a 2022 RCT, red yeast rice for 12 weeks lowered hs-CRP by ~20% in hyperlipidemic participants, alongside improved gut microbiota composition [2][40]. In rodent models, red yeast rice reduced hepatic lipid accumulation by 40% in high-fat diet-fed mice via AMPK pathway activation [2][41]. These findings are promising but need robust human clinical validation.

Blood Pressure

Several studies have noted blood pressure-lowering effects of red yeast rice, though this is not its primary indication. The Mazza 2018 study found blood pressure reductions with red yeast rice + CoQ10 + Mediterranean diet [1][21], and the Minamizuka 2021 study of low-dose red yeast rice also observed apparent BP reductions [1][23]. However, these effects have not been rigorously isolated from other components of these interventions.

Recommended Dosing

Clinical Trial Dosing Summary

Study	Daily RYR Dose	Total Lovastatin	Regimen
Heber 1999	2,400 mg (4 x 600 mg)	~7 mg	Twice daily
Lu / CCSPS 2008	1,200 mg (4 x 300 mg)	10-12.8 mg	Three times daily
Becker 2008	2,400-3,600 mg	18-27 mg	Twice daily
Becker 2009	1,800 mg (3 x 600 mg)	~4.9 mg	Twice daily
Becker 2010	4,800 mg (8 x 600 mg)	~14.2 mg	Twice daily
Venero 2010	1,200 mg	Variable	Once at bedtime
Minamizuka 2021	200 mg	~2 mg	Once after dinner
Mazza 2018	Not specified	10 mg (+ CoQ10)	With Mediterranean diet

Typical effective dose: 1,200-2,400 mg/day of red yeast rice, divided into two doses, providing 3-10 mg monacolin K daily. Clinical trials demonstrate 15-25% LDL reductions over 6-12 weeks [1][2].

Minimum effective dose: 200 mg/day providing ~2 mg lovastatin showed meaningful reduction in one small study, but requires confirmation [1][23].

CCSPS regimen (strongest evidence): 1,200 mg/day Xuezhikang providing 10-12.8 mg total lovastatin — the only regimen with cardiovascular mortality benefit evidence [9].

Expert Panel Recommendations (2022)

The International Lipid Expert Panel issued recommendations [1][43]:

May be considered for:

• Adults with suboptimal lipid profile despite diet/lifestyle who are unwilling to take statins
• Adults with confirmed statin intolerance

Should NOT be used by:

• Those with hypersensitivity to monacolin K/lovastatin
• Acute liver disease or severe renal impairment (eGFR <30 mL/min)
• Muscle disease
• Children and adolescents
• Women who are pregnant, may become pregnant, or are breastfeeding

The panel suggested daily doses contain no more than 3 mg monacolins for safety, though this relatively low dose may also be less effective [1][43].

European Regulatory Limit

As of June 2023, EFSA requires red yeast rice products in Europe contain less than 3 mg monacolins per daily serving with label disclosure [1][7]. In July 2024, the European Commission revoked the health claim for monacolin K at 10 mg/day [2][44]. In February 2025, EFSA concluded monacolins pose significant risks at any dose, potentially leading to prohibition by mid-2026 [2][44].

How to Take Red Yeast Rice

• Divide the dose: Take in two doses per day rather than all at once [1]
• Bedtime dose: Most cholesterol synthesis occurs at night; take the second dose at bedtime [1][17]
• Consider CoQ10: Monacolins may deplete CoQ10 via the mevalonate pathway [1][2][13]
• Do not combine with prescription statins [1]

Product Selection

• Choose third-party tested products verified to be citrinin-free [1][4]
• Target ~1.6 to 5.7 mg total lovastatin per 600 mg red yeast rice [1]
• Be aware that monacolin content varies between batches [1][8]
• Low monacolin levels are typically associated with higher citrinin contamination [1]

Safety and Side Effects

Common Side Effects

Red yeast rice can cause digestive upset including heartburn, gas, stomach pain, bloating, nausea, and diarrhea [1][16][45]. Headache and dizziness have also been reported [1][45]. A Netherlands adverse event review (2007-2020) found 33 of 187 reports were gastrointestinal, including three serious pancreatitis cases. Most occurred about 3 weeks after starting supplementation [1][45]. In pharmacovigilance analyses, GI reactions occurred in ~12% of reports [2][46].

Muscle Problems (Myopathy and Rhabdomyolysis)

Like prescription statins, monacolins can cause muscle problems from mild myalgia to rare rhabdomyolysis (rapid muscle breakdown causing kidney damage) [1][4][16]. The Netherlands review found 64 of 187 adverse reactions were musculoskeletal, including two cases of rhabdomyolysis. Most occurred about 2.5 weeks after starting supplementation [1][45]. In Italy, muscle and liver injury were among the most common adverse events; two-thirds occurred within two months of use [1][47].

FDA database analysis identified 1,300 FAERS reports (primarily hepatic issues) and 159 CAERS reports (mainly musculoskeletal, including 27 rhabdomyolysis/myopathy cases) [2][46].

Severe case: A 68-year-old Slovenian woman developed severe rhabdomyolysis just 2 days after starting red yeast rice providing only 2.9 mg monacolin K/day. Her physicians noted older women may be particularly susceptible [1][48].

EFSA's 2018 assessment noted significant safety concerns at 10 mg/day monacolin intake, with severe reactions reported at doses as low as 3 mg/day [1][7]. In 2025, EFSA concluded monacolins pose risks at any dose in susceptible individuals [2][44].

Liver Injury (Hepatotoxicity)

Several hepatitis cases have been associated with red yeast rice [1][16][45][50]:

• A US woman taking two 600 mg capsules twice daily for ~4 months — resolved after discontinuation [1][51]
• An Italian woman taking guggulsterol + red yeast rice (15-30 mg monacolin K/day) for 6 months — she had prior elevated enzymes on prescription lovastatin [1][52]
• A 64-year-old Detroit woman, 6 weeks after starting red yeast rice (NOW Foods 1,200 mg 10:1 concentrate) — resolved with IV methylprednisolone [1][53]
• A 71-year-old French woman — fatal liver failure after 3 months on a supplement containing 10 mg monacolin K plus Garcinia cambogia [1][54]

Liver damage with prescription statins occurs at ~1% incidence [1][55]. Red yeast rice should be avoided by people with existing liver problems [1][16].

Myasthenia Gravis

Red yeast rice may worsen myasthenia gravis symptoms. A 69-year-old man experienced significant worsening (eyelid/head drooping, difficulty chewing/swallowing) after just 6 days on 450 mg/day [1][56]. Prescription statins have also been reported to worsen this condition [56].

Sleep Disturbances

The lovastatin in red yeast rice could potentially cause insomnia. Studies have reported sleep problems with fat-soluble statins (lovastatin, simvastatin) that cross the blood-brain barrier more easily than water-soluble statins [1][57][58].

Diabetes Risk

While statins increase diabetes risk by 2.2-fold [1][37], red yeast rice appears to carry much lower risk. A large Taiwanese study found 54% lower diabetes risk with red yeast rice vs. lovastatin over 5 years, with higher doses actually associated with lower risk [1][38].

Citrinin Contamination

Citrinin is a kidney-toxic mycotoxin found in some red yeast rice products [1][2][4][5]:

• 2021 analysis: Only 1 of 37 products met EU citrinin limits; 4 labeled "citrinin-free" were contaminated [4][5][59]
• 2009-2012 Taiwan survey: Citrinin detected in 69% of raw materials, 35.1% of semi-processed, 5.7% of finished products [2][60]
• EU maximum: 100 micrograms/kg since 2014 [2][61]
• Low monacolin levels typically correlate with higher citrinin contamination [1]

The 2024 Japan Kobayashi Pharmaceutical Incident

Contaminated red yeast rice supplements from Kobayashi Pharmaceutical in Japan were linked to over 100 hospitalizations and multiple deaths due to puberulic acid contamination [2][62]. This prompted nationwide recalls and enhanced safety testing mandates. Japan's Ministry of Health updated guidelines in December 2024 for dissolution testing and impurity controls on mold-fermented supplements [2][62].

Special Populations

• Pregnancy/breastfeeding: Avoid — no safety studies available [1][4][43]
• Normal cholesterol: No known benefit for maintaining already healthy levels [1]
• Kidney disease (eGFR <30): Avoid due to citrinin risk and statin-like effects [43]

Monitoring Recommendations

Mirror statin monitoring protocols [2][16]:

• Baseline and periodic liver function tests (ALT, AST)
• Creatine kinase (CK) if muscle symptoms develop
• Serum lipid profiles to evaluate efficacy
• Renal function monitoring for pre-existing kidney conditions
• Report unexplained muscle pain, weakness, dark urine, or jaundice promptly

Drug Interactions

Red yeast rice contains monacolin K, chemically identical to lovastatin. Its drug interactions mirror those of prescription lovastatin [1][2][16].

Prescription Statins

Combining red yeast rice with prescription statins increases all statin-related risks and should be avoided [1][16].

CYP3A4 Inhibitors (Increase Toxicity Risk)

Substance	Notes
Grapefruit juice	Significantly inhibits CYP3A4; avoid with red yeast rice [1][16]
Macrolide antibiotics (erythromycin, clarithromycin)	Impair monacolin K metabolism [2][16]
Azole antifungals (ketoconazole, itraconazole)	Impair monacolin K metabolism [1][2][16]
HIV protease inhibitors	Increase lovastatin plasma concentrations [1][16]
Cyclosporine, immunosuppressants	Heighten rhabdomyolysis risk [2][16]
Nefazodone (Serzone)	Antidepressant interaction [1]
Olaparib (Lynparza)	Weak CYP3A4 inhibitor; theoretical risk. Inform your doctor [1][63]

CYP3A4 Inducers (Reduce Effectiveness)

St. John's wort induces CYP3A4, potentially reducing red yeast rice effectiveness. Avoid the combination [1].

Fibrates

Fibrates (e.g., gemfibrozil) potentiate myopathy risk through pharmacodynamic synergy with lovastatin [1][2][16].

Anticoagulants

Potential for altered warfarin pharmacokinetics; INR monitoring advised [2][16].

Other Interactions

• Blood pressure medications: Potential additive BP-lowering with beta-blockers; monitor [2]
• Alcohol: May exacerbate hepatotoxicity from monacolin K [2][16]
• CoQ10 depletion: Monacolins block CoQ10 synthesis; supplementation advisable [1][2][13]
• Hepatotoxic supplements: Caution with kava, high-dose acetaminophen due to additive liver risk [2][16]

Dietary Sources

Traditional Food Uses

• Chinese cuisine: Char siu, Peking duck, fermented bean curd, rice vinegar, salted meats, pickled vegetables, fish sauces [2][3]
• Rice wines: Anchu, hong qu mi jiu, Fujian red wine chicken [2][3]
• Japanese/Okinawan: Tofuyo (fermented tofu), red rice cakes, red laojiu [2][3]
• Korean: Certain fermentation practices and kimchi variants [2]
• Thai: Known as angkak, used in folk medicine and cooking [2]

Traditional Chinese Medicine

Known as Hong Qu or Dan Qu, classified as sweet and warm, targeting liver, spleen, and large intestine. Used to strengthen the spleen and stomach, promote digestion, invigorate blood circulation, and resolve blood stasis. Traditional dosage in decoctions: 6-12 grams. Features in over two dozen TCM prescriptions [2][3].

Food vs. Supplement Distinction

Traditional culinary red yeast rice typically provides only trace amounts of monacolins. The health effects of red yeast rice as a food ingredient have not been well studied separately from its role as a supplement [4][5].

Other Cholesterol-Lowering Supplements and Foods

Other natural products that may help lower cholesterol include oats and oat bran, soy protein, flaxseed, psyllium fiber, plant stanols and sterols, fish oil, and garlic [1]. Dr Brad Stanfield's MicroVitamin+ Powder includes 2.5 g of psyllium husk — a soluble fiber shown in a Cochrane systematic review to reduce cardiovascular disease risk factors and help maintain healthy cholesterol levels.

References

1. ConsumerLab. "Red Yeast Rice Supplements Review." Accessed 2026. https://www.consumerlab.com/reviews/red-yeast-rice-supplements-review/red-yeast-rice/. Studies cited: Heber (Am J Clin Nutr 1999), Becker (Mayo Clinic Proc 2008; Ann Int Med 2009; Am Heart J 2013), Lu (Am J Cardiol 2008), Mazza (Biomed Pharmacother 2018), Minamizuka (Asia Pac J Clin Nutr 2021), Venero (Am J Cardiol 2010), Banach (Pharmacol Res 2022), and others.

2. Grokipedia. "Red yeast rice." https://grokipedia.com/page/Red_yeast_rice

3. Zhu B, Qi F, Wu J, et al. "Red yeast rice: a systematic review of the traditional uses, chemistry, pharmacology, and quality control." Frontiers in Pharmacology. 2019;10:1449. https://pubmed.ncbi.nlm.nih.gov/31866873/

4. National Center for Complementary and Integrative Health (NCCIH). "Red Yeast Rice: What You Need To Know." Updated November 2022. https://www.nccih.nih.gov/health/red-yeast-rice

5. Cohen PA, Avula B, Khan IA. "Variability in strength of red yeast rice supplements." European Journal of Preventive Cardiology. 2017;24(13):1431-1434. https://pubmed.ncbi.nlm.nih.gov/28622038/

6. Song J, Luo J, Ma Z, et al. "Quality and authenticity control of functional red yeast rice." Molecules. 2019;24(10):1944. https://pubmed.ncbi.nlm.nih.gov/31117211/

7. European Food Safety Authority (EFSA). "Scientific opinion on the safety of monacolins in red yeast rice." EFSA Journal. 2018;16(8):e05368. https://efsa.onlinelibrary.wiley.com/doi/full/10.2903/j.efsa.2018.5368

8. Gordon RY, Cooperman T, Obermeyer W, et al. "Marked variability of monacolin levels in commercial red yeast rice products." Archives of Internal Medicine. 2010;170(19):1722-1727. https://pubmed.ncbi.nlm.nih.gov/20975018/

9. Lu Z, Kou W, Du B, et al. "Effect of Xuezhikang on coronary events in a Chinese population with previous myocardial infarction." American Journal of Cardiology. 2008;101(12):1689-1693. https://pubmed.ncbi.nlm.nih.gov/18549841/

10. ConsumerLab testing data as cited in Gordon et al. 2010.

11. Yuan R, et al. "Red yeast rice preparations reduce mortality, major cardiovascular adverse events, and risk factors for metabolic syndrome." Frontiers in Pharmacology. 2022;13:744928. https://pubmed.ncbi.nlm.nih.gov/35462913/

12. Liu S-F, et al. "Ankascin 568-R Plus and metabolic syndrome." Journal of Food and Drug Analysis. 2018.

13. Red yeast rice + CoQ10 combination trial (2016). Reviewed in ConsumerLab and Grokipedia.

14. Nattokinase + red yeast rice combination studies. 2009 RCT and 2024 coronary artery disease data. Cited in Grokipedia.

15. Liu, et al. "Red yeast rice plus nattokinase in coronary artery disease." Frontiers in Nutrition. 2024.

16. Vrolijk MF, et al. "Adverse reactions to dietary supplements containing red yeast rice." British Journal of Clinical Pharmacology. 2020.

17. Wallace A, et al. "Timing of statin administration." BMJ. 2003.

18. Chen C-H, et al. "Improved dissolution rate and oral bioavailability of lovastatin in red yeast rice products." International Journal of Pharmaceutics. 2013;444(1-2):18-24.

19. Heber D, et al. "Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement." American Journal of Clinical Nutrition. 1999;69(2):231-236. https://pubmed.ncbi.nlm.nih.gov/9989685/

20. Becker DJ, et al. "Red yeast rice for dyslipidemia in statin-intolerant patients." Mayo Clinic Proceedings. 2008.

21. Mazza A, et al. "Monacolin K and CoQ10 supplementation in hypertensive and hypercholesterolemic subjects." Biomedicine & Pharmacotherapy. 2018;100:324-331. https://pubmed.ncbi.nlm.nih.gov/29448205/

22. Early 2000s RCT of 74 hypercholesterolemic patients. Cited in Grokipedia.

23. Minamizuka T, et al. "Low-dose red yeast rice for cholesterol lowering." Asia Pacific Journal of Clinical Nutrition. 2021.

24. 2022 meta-analysis of 15 high-quality RCTs (n=1,012). Cited in Grokipedia.

25. 2024 systematic review of 14 double-blinded RCTs (n=705). Cited in Grokipedia.

26. Parra-Virto A, et al. "Red yeast rice and berberine as adjunct therapy." Clinica e Investigacion en Arteriosclerosis. 2018.

27. Becker DJ, et al. "Red yeast rice with or without plant sterols." American Heart Journal. 2013.

28. 2020 meta-analysis of 7 RCTs (n=10,699 MI patients). Cited in Grokipedia.

29. 2024 meta-analysis in secondary prevention. Cited in Grokipedia.

30. Becker DJ, et al. "Red yeast rice in statin-intolerant patients." Annals of Internal Medicine. 2009;150(12):830-839. https://pubmed.ncbi.nlm.nih.gov/19528562/

31. Xue Y, et al. "Red yeast rice versus simvastatin." BMC Cardiovascular Disorders. 2017.

32. Venero CV, et al. "Red yeast rice in statin-intolerant patients." American Journal of Cardiology. 2010;105(5):664-666. https://pubmed.ncbi.nlm.nih.gov/20185013/

33. 2023-2024 trial in statin-intolerant familial hypercholesterolemia (n=55). Cited in Grokipedia.

34. Systematic review comparing red yeast rice with simvastatin. Cited in Grokipedia.

35. Chang Y-Y, et al. "Liver cirrhosis in patients treated with red yeast rice." Journal of Multidisciplinary Healthcare. 2024.

36. 2024 cohort (n>100,000) of liver cirrhosis incidence. Cited in Grokipedia.

37. Zigmont VA, et al. "Statin use and new-onset type 2 diabetes." Diabetes/Metabolism Research and Reviews. 2019. https://pubmed.ncbi.nlm.nih.gov/30864237/. Also: FDA Drug Safety Communication, 2012.

38. Chen J-Y, et al. "Red yeast rice vs. lovastatin and diabetes risk." Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2020.

39. 2022 meta-analysis of red yeast rice and glucose metabolism. Cited in Grokipedia.

40. 2022 RCT of red yeast rice on inflammation and gut microbiota. Cited in Grokipedia.

41. 2022 rodent study of red yeast rice on NAFLD. Cited in Grokipedia.

42. Becker DJ, et al. 2010 red yeast rice dosing study.

43. Banach M, et al. "International Lipid Expert Panel recommendations on red yeast rice." Pharmacological Research. 2022. https://pubmed.ncbi.nlm.nih.gov/35378258/

44. European Commission revocation (July 2024); EFSA 2025 opinion. Commission Regulation (EU) 2022/860.

45. Vrolijk MF, et al. "Adverse reactions to red yeast rice supplements." British Journal of Clinical Pharmacology. 2020.

46. Raschi E, et al. "Adverse events to food supplements containing red yeast rice: FAERS and CAERS analysis." Drug Safety. 2018;41(8):745-752.

47. Mazzanti G, et al. "Adverse reactions to red yeast rice products in Italy." British Journal of Pharmacology. 2017.

48. Kurnik D, et al. "Severe rhabdomyolysis with low-dose red yeast rice." Drug, Healthcare and Patient Safety. 2025.

49. Wigger-Alberti W, et al. "Allergic reaction to yeast in red yeast rice." Allergy. 1999.

50. LiverTox. "Red Yeast Rice." NCBI Bookshelf. 2016. https://www.ncbi.nlm.nih.gov/books/NBK548336/

51. Roselle H, et al. "Hepatotoxicity from red yeast rice." Annals of Internal Medicine. 2008.

52. Grieco A, et al. "Hepatitis from red yeast rice." Journal of Hepatology. 2009.

53. Loubser L, et al. "Acute hepatitis from red yeast rice." BMJ Case Reports. 2019.

54. ANSES. Report on fatal liver failure from red yeast rice + Garcinia cambogia supplement. 2020.

55. Gillett RC, et al. "Statin-induced liver damage." American Family Physician. 2011.

56. Dombremez E, et al. "Myasthenia gravis exacerbation with red yeast rice." Revue Neurologique (Paris). 2018. Also: Gale J, et al. Journal of Clinical Neuroscience. 2014.

57. Golomb BA, et al. "Statin-associated insomnia." American Journal of Cardiovascular Drugs. 2008.

58. Vgontzas AN, et al. "Lovastatin and sleep." Clinical Pharmacology & Therapeutics. 1991.

59. Twaruzek M, et al. "Dietary supplements based on red yeast rice — a source of citrinin?" Toxins. 2021;13(7):497. https://pubmed.ncbi.nlm.nih.gov/34357962/

60. 2009-2012 Taiwan citrinin survey (302 samples). Cited in Grokipedia.

61. European Commission citrinin limit (100 micrograms/kg), established 2014.

62. 2024 Kobayashi Pharmaceutical incident. Japan Food Labeling Standards (Sept 2024); Ministry of Health guidelines (Dec 2024). Cited in Grokipedia.

63. Brokaar L, et al. "Olaparib and CYP3A4 interaction with red yeast rice." Exploratory Research in Clinical and Social Pharmacy. 2025.

64. Fogacci F, et al. "Safety of red yeast rice supplementation: systematic review." Pharmacological Research. 2019;143:1-16.

65. Yinhua M, et al. "Red yeast rice and diabetes risk." PLOS ONE. 2014.

66. Wang J, et al. "Red yeast rice side effects." Current Therapeutic Research. 1997.

67. Karl M, et al. "Red yeast rice side effects." Journal of Clinical Lipidology. 2012.

68. Liu J, et al. "Chinese red yeast rice for primary hyperlipidemia." Chinese Medicine. 2006.

69. Righetti L, et al. "Risk assessment of RYR food supplements." Frontiers in Nutrition. 2021;8:792529.